Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression

Human Psychopharmacology

Volumn 18, Issue 6, 2003, Pages 479-482

  Morishita, Shigeru ^a   Arita, Seizaburo ^b  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Depression; Fluvoxamine; Milnacipran; Onset; Paroxetine

Indexed keywords

ANTIDEPRESSANT AGENT; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HOSPITAL DEPARTMENT; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; SWEATING;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0042926569     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.508     Document Type: Article

References (12)

1. Ansseau M, Papart P, Trioisfontaines B, et al. 1994. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 114: 131-137.
2. Clerc G, Milnacipran/Fluvoxamine Study Groups. 2001. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 16: 145-151.
3. Feighner JP. 1994. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 55(Suppl. A): 62-68.
4. Fukuchi T, Kanemoto K. 2002. Differential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control study. Int Clin Psychopharmacol 17: 53-58.
5. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
6. Kiev A, Feiger A. 1997. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146-152.
7. Morishita S, Arita S. 2003. Suitable dose and duration of fluvoxamine administration to treat depression. Psychiat Clin Neurosci 57: 179-183.
8. Nelson JCN. 1997. Safety and tolerability of the new antidepressants. J Clin Psychiatry 58(Suppl. 6): 26-31.
9. Prien RF, Carpenter LL, Kupfer DJ. 1991. The definition and operational criteria for treatment outcome of major depressive disorder: a review of the current research literature. Arch Gen Psychiatry 48: 796-800.
10. Puech A, Montgomery SA, Prost JF, et al. 1997. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108.
11. Quitkin FM, McGrath PJ, Stewart JW, et al. 1996. Chronological milestones to guide drug change: when should clinicians switch antidepressant? Arch Gen Psychiatry 53: 785-792.
12. Stassen HH, Angst J, Delini-Stula A. 1994. Severity of baseline and onset of improvement in depression: meta-analysis of imipramine and mochlobemide versus placebo. Eur Psychiatry 9(Suppl. 3): 129-136.